Corvus Pharmaceuticals, Inc. announced new preclinical data for ciforadenant, the Company's adenosine 2A receptor inhibitor, highlighting its mechanism of action and synergy with immune checkpoint inhibitors via combination with anti-CTLA-4 and anti-PD-1 therapies. The data is being presented in a poster at the 2nd Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference, which is taking place June 28-30, 2023 in Kyoto, Japan. The new ciforadenant preclinical data was presented by Dan Li, Ph.D., Senior Scientist at Corvus, in a poster session (abstract #12-1) at the JCA-AACR conference.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.19 USD | -1.35% | +11.73% | +24.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.43% | 109M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- CRVS Stock
- News Corvus Pharmaceuticals, Inc.
- Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference